Literature DB >> 10975801

HMG-1 as a mediator of acute lung inflammation.

E Abraham1, J Arcaroli, A Carmody, H Wang, K J Tracey.   

Abstract

Acute inflammatory lung injury is often a delayed complication of critical illness and is associated with increased mortality. High mobility group-1 (HMG-1) protein, in addition to its role as a transcriptional regulatory factor, has recently been identified as a late mediator of endotoxin lethality. In the present studies, HMG-1 given intratracheally produced acute inflammatory injury to the lungs, with neutrophil accumulation, the development of lung edema, and increased pulmonary production of IL-1beta, TNF-alpha, and macrophage-inflammatory protein-2. In endotoxin-induced acute lung inflammation, administration of anti-HMG-1 Abs either before or after endotoxin exposure decreased the migration of neutrophils to the lungs as well as lung edema. These protective effects of anti-HMG-1 were specific, because pulmonary levels of IL-1beta, TNF-alpha, or macrophage-inflammatory protein-2 were not decreased after therapy with anti-HMG-1. Together, these findings indicate that HMG-1 is a distal mediator of acute inflammatory lung injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10975801     DOI: 10.4049/jimmunol.165.6.2950

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  267 in total

Review 1.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

2.  Extracellular processing of amphoterin generates a peptide active on erythroleukaemia cell differentiation.

Authors:  B Sparatore; M Patrone; M Passalacqua; M Pedrazzi; D Gaggero; S Pontremoli; E Melloni
Journal:  Biochem J       Date:  2001-07-15       Impact factor: 3.857

3.  Immunological identification of endogenous peptides secreted by surviving slices of rat olfactory cortex.

Authors:  A A Mokrushin; A Plekhanov
Journal:  Dokl Biol Sci       Date:  2001 May-Jun

4.  Immunomodulatory drugs regulate HMGB1 release from activated human monocytes.

Authors:  Hanna Schierbeck; Heidi Wähämaa; Ulf Andersson; Helena Erlandsson Harris
Journal:  Mol Med       Date:  2010-04-09       Impact factor: 6.354

5.  High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy.

Authors:  Yoko Oyama; Teruto Hashiguchi; Noboru Taniguchi; Salunya Tancharoen; Tomonori Uchimura; Kamal K Biswas; Ko-Ichi Kawahara; Takao Nitanda; Yoshihisa Umekita; Martin Lotz; Ikuro Maruyama
Journal:  Lab Invest       Date:  2010-03-15       Impact factor: 5.662

6.  Ischemic preconditioning attenuates acute lung injury after partial liver transplantation.

Authors:  Qinlong Liu; Hasibur Rehman; Yasodha Krishnasamy; John J Lemasters; Zhi Zhong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-04-20

7.  Caging a Beast in the Inflammation Arena: Use of Chinese Medicinal Herbs to Inhibit a Late Mediator of Lethal Sepsis, HMGB1.

Authors:  Shu Zhu; Wei Li; Jianhua Li; Andrew E Sama; Haichao Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-20

8.  Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury.

Authors:  Peter J Smit; Weidun A Guo; Bruce A Davidson; Barbara A Mullan; Jadwiga D Helinski; Paul R Knight
Journal:  J Surg Res       Date:  2014-04-08       Impact factor: 2.192

9.  The multiple organ dysfunction syndrome and late-phase mortality in sepsis.

Authors:  Joshua A Englert; Mitchell P Fink
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

10.  Disruption of Parasite hmgb2 Gene Attenuates Plasmodium berghei ANKA Pathogenicity.

Authors:  Sylvie Briquet; Nadou Lawson-Hogban; Bertrand Boisson; Miguel P Soares; Roger Péronet; Leanna Smith; Robert Ménard; Michel Huerre; Salah Mécheri; Catherine Vaquero
Journal:  Infect Immun       Date:  2015-04-27       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.